$AHS (AMN Healthcare Services Inc.)

$AHS {{ '2016-09-19T15:34:35+0000' | timeago}} • Announcement

$AHS' unit AMN Healthcare plans to make private offering of $300MM of senior notes due 2024. The senior notes will be guaranteed by its affiliates that guarantee its credit facilities. AMN plans to use proceeds to repay $113.8MM of certain existing term loan and $182.5MM under revolving portion of credit facilities and pay fees and expenses.

$EW {{ '2017-07-26T20:43:20+0000' | timeago}} • Announcement

For 3Q17, $EW projects underlying sales, adjusting for the impact of Germany stocking sales consumption, to be between $810-850MM, and adjusted earnings per share of $0.80 to $0.90.

$EW {{ '2017-07-26T20:42:56+0000' | timeago}} • Announcement

For FY17, $EW's full year sales estimate is now at the high end of its previous $3.2-3.4Bil guidance. Edwards Lifesciences Corp is also raising its estimate for FY17 adjusted earnings per share to $3.65-3.85, from $3.43-3.55.

$EW {{ '2017-07-26T20:40:21+0000' | timeago}} • Announcement

With strong demand for TAVR therapy resulted in total sales growth of 15% on an underlying basis, $EW's 2Q17 sales soared 11% to $841.8MM. Net income for the quarter jumped 47% to $186.1MM or $0.86 per diluted share. Adjusted earnings per share grew 42.1% to $1.08 while underlying sales rose 15% to about $864MM.

$VRTX {{ '2017-07-26T20:38:11+0000' | timeago}} • Announcement

$VRTX also reviewed its recent progress toward treating all people with cystic fibrosis, including the completion of an asset purchase agreement with Concert Pharmaceuticals for worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis.

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$VRTX {{ '2017-07-26T20:36:21+0000' | timeago}} • Announcement

$VRTX lifted 2017 non-GAAP combined research & development and selling, general & administrative expenses outlook to $1.33-1.36Bil from $1.25-1.30Bil, and GAAP combined R&D and SG&A expenses estimate to $1.79-1.92 from $1.55-1.70. The updated forecast reflects the progression of the company's cystic fibrosis portfolio.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$VRTX {{ '2017-07-26T20:33:48+0000' | timeago}} • Announcement

$VRTX expects 2017 total cystic fibrosis product revenue of $1.84-2.07Bil, comprised of Orkambi and Kalydeco product revenues. $VRTX still expects 2017 product revenue for Orkambi of $1.1-1.3Bil and for Kalydeco of $740-770MM.

$VRTX {{ '2017-07-26T20:30:18+0000' | timeago}} • Announcement

$VRTX's net product revenues from cystic fibrosis therapy Orkambi for 2Q17 increased to $324.4MM from $245.5MM last year. This was primarily driven by the continued uptake in the medicine globally and additional uptake in people with cystic fibrosis ages 6 to 11 in the U.S., where approval was received in September 2016.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$VRTX {{ '2017-07-26T20:26:38+0000' | timeago}} • Announcement

$VRTX reported net income for 2Q17 of $31.17MM or $0.07 per share compared to a loss of $64.53MM or $0.26 per share last year. This swing in results was driven by higher revenue as well as a decline in interest expenses. Revenue grew to $544.14MM from $431.61MM. Non-GAAP EPS increased to $0.39 from $0.24.

$AMGN {{ '2017-07-26T19:57:57+0000' | timeago}} • Webcast

$AMGN has $39Bil cash on balance sheet, with no intention to consummate M&A transactions or repaying debt right now. The vast majority of cash is sitting offshore and the company is not considering to repatriate it under the current US tax system. The company said it will take a look at deploying the cash when some progress is made on tax reform.

$AMGN {{ '2017-07-26T19:34:18+0000' | timeago}} • Webcast

In 2Q17, $AMGN had a strong volume-driven growth from Prolia and other recently launched drugs including KYPROLIS and Repatha. Prolia sales increased 15% with an 18% volume growth YoY, with share gains in both the US and international markets.

$BIIB {{ '2017-07-26T13:59:55+0000' | timeago}} • Webcast

In multiple sclerosis, $BIIB's 2Q17 global TECFIDERA revenue growth was driven by volume growth, while patient growth in TECFIDERA was driven by its newly launched markets such as Italy, Poland & Japan. For FY17 ex-US, $BIIB expects SPINRAZA revenues to be modest, mainly from Germany and Japan. However, patient intake in the US is expected to grow.

$BIIB {{ '2017-07-26T13:46:38+0000' | timeago}} • Webcast

$BIIB's priority for capital deployment going forward is to invest in building its pipeline across its core growth areas like Alzheimer's, Parkinson's and neuromuscular disease and emerging areas like pain, ophthalmology and neuropsychiatry. $BIIB expects to have about $400MM available by 2019 for R&D and commercial value creation opportunities.

$TGNA {{ '2017-07-26T13:25:06+0000' | timeago}} • Announcement

$TGNA has declared a dividend of 7 cents per share, payable on Oct 2, 2017 to stockholders of record as on Sept 8, 2017. The company expects to pay a regular cash dividend of $0.28 per share annually as announced leading up to the spin-off of Cars.com, which was completed on May 31, 2017.

$BAX {{ '2017-07-26T12:58:04+0000' | timeago}} • Announcement

$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.

$BAX {{ '2017-07-26T12:56:58+0000' | timeago}} • Announcement

As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.

$BAX {{ '2017-07-26T12:55:25+0000' | timeago}} • Announcement

$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.

$BAX {{ '2017-07-26T12:54:23+0000' | timeago}} • Announcement

$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.

Recent Transcripts

RHI (Robert Half International Inc.)
Tuesday, July 25 2017 - 9:00pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
HCA (HCA Holdings, Inc.)
Tuesday, July 25 2017 - 2:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
CTG (Computer Task Group Inc.)
Tuesday, July 25 2017 - 12:30pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
MAN (ManpowerGroup Inc.)
Monday, July 24 2017 - 12:30pm
RECN (Resources Connection, Inc.)
Thursday, July 20 2017 - 9:00pm
CDI (CDI Corp.)
Wednesday, May 10 2017 - 8:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
TGNA (TEGNA Inc.)
Tuesday, May 9 2017 - 3:00pm
FVE (Five Star Quality Care Inc.)
Friday, May 5 2017 - 2:00pm
SEM (Select Medical Holdings Corporation)
Friday, May 5 2017 - 1:00pm
AHS (AMN Healthcare Services Inc.)
Thursday, May 4 2017 - 9:00pm
HSON (Hudson Global, Inc)
Thursday, May 4 2017 - 2:00pm
MD (MEDNAX, Inc.)
Thursday, May 4 2017 - 2:00pm
KND (Kindred Healthcare Inc.)
Thursday, May 4 2017 - 1:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Wednesday, May 3 2017 - 1:30pm
ADP (Automatic Data Processing Inc)
Wednesday, May 3 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm

AlphaGraphics you may like